132 related articles for article (PubMed ID: 24788101)
1. Molecular pathways: harnessing E2F1 regulation for prosenescence therapy in p53-defective cancer cells.
Laine A; Westermarck J
Clin Cancer Res; 2014 Jul; 20(14):3644-50. PubMed ID: 24788101
[TBL] [Abstract][Full Text] [Related]
2. Senescence sensitivity of breast cancer cells is defined by positive feedback loop between CIP2A and E2F1.
Laine A; Sihto H; Come C; Rosenfeldt MT; Zwolinska A; Niemelä M; Khanna A; Chan EK; Kähäri VM; Kellokumpu-Lehtinen PL; Sansom OJ; Evan GI; Junttila MR; Ryan KM; Marine JC; Joensuu H; Westermarck J
Cancer Discov; 2013 Feb; 3(2):182-97. PubMed ID: 23306062
[TBL] [Abstract][Full Text] [Related]
3. E2F-1 is a critical modulator of cellular senescence in human cancer.
Park C; Lee I; Kang WK
Int J Mol Med; 2006 May; 17(5):715-20. PubMed ID: 16596252
[TBL] [Abstract][Full Text] [Related]
4. E2F1-dependent pathways are involved in amonafide analogue 7-d-induced DNA damage, G2/M arrest, and apoptosis in p53-deficient K562 cells.
Li Y; Shao J; Shen K; Xu Y; Liu J; Qian X
J Cell Biochem; 2012 Oct; 113(10):3165-77. PubMed ID: 22593008
[TBL] [Abstract][Full Text] [Related]
5. Translating DNA damage into cancer cell death-A roadmap for E2F1 apoptotic signalling and opportunities for new drug combinations to overcome chemoresistance.
Engelmann D; Pützer BM
Drug Resist Updat; 2010; 13(4-5):119-31. PubMed ID: 20675184
[TBL] [Abstract][Full Text] [Related]
6. The E2F1/Rb and p53/MDM2 pathways in DNA repair and apoptosis: understanding the crosstalk to develop novel strategies for prostate cancer radiotherapy.
Udayakumar T; Shareef MM; Diaz DA; Ahmed MM; Pollack A
Semin Radiat Oncol; 2010 Oct; 20(4):258-66. PubMed ID: 20832018
[TBL] [Abstract][Full Text] [Related]
7. Regulation of replicative and stress-induced senescence by RSK4, which is down-regulated in human tumors.
López-Vicente L; Armengol G; Pons B; Coch L; Argelaguet E; Lleonart M; Hernández-Losa J; de Torres I; Ramon y Cajal S
Clin Cancer Res; 2009 Jul; 15(14):4546-53. PubMed ID: 19584160
[TBL] [Abstract][Full Text] [Related]
8. E2F1 apoptosis counterattacked: evil strikes back.
Pützer BM; Engelmann D
Trends Mol Med; 2013 Feb; 19(2):89-98. PubMed ID: 23219173
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic targeting of replicative immortality.
Yaswen P; MacKenzie KL; Keith WN; Hentosh P; Rodier F; Zhu J; Firestone GL; Matheu A; Carnero A; Bilsland A; Sundin T; Honoki K; Fujii H; Georgakilas AG; Amedei A; Amin A; Helferich B; Boosani CS; Guha G; Ciriolo MR; Chen S; Mohammed SI; Azmi AS; Bhakta D; Halicka D; Niccolai E; Aquilano K; Ashraf SS; Nowsheen S; Yang X
Semin Cancer Biol; 2015 Dec; 35 Suppl(Suppl):S104-S128. PubMed ID: 25869441
[TBL] [Abstract][Full Text] [Related]
10. Role of p53 and p21waf1/cip1 in senescence-like terminal proliferation arrest induced in human tumor cells by chemotherapeutic drugs.
Chang BD; Xuan Y; Broude EV; Zhu H; Schott B; Fang J; Roninson IB
Oncogene; 1999 Aug; 18(34):4808-18. PubMed ID: 10490814
[TBL] [Abstract][Full Text] [Related]
11. The E2F family and the role of E2F1 in apoptosis.
Wu Z; Zheng S; Yu Q
Int J Biochem Cell Biol; 2009 Dec; 41(12):2389-97. PubMed ID: 19539777
[TBL] [Abstract][Full Text] [Related]
12. E2F1 suppresses skin carcinogenesis via the ARF-p53 pathway.
Russell JL; Weaks RL; Berton TR; Johnson DG
Oncogene; 2006 Feb; 25(6):867-76. PubMed ID: 16205640
[TBL] [Abstract][Full Text] [Related]
13. E2F1 mediates ectopic proliferation and stage-specific p53-dependent apoptosis but not aberrant differentiation in the ocular lens of Rb deficient fetuses.
Liu Y; Zacksenhaus E
Oncogene; 2000 Dec; 19(52):6065-73. PubMed ID: 11146559
[TBL] [Abstract][Full Text] [Related]
14. Escape from premature senescence is not sufficient for oncogenic transformation by Ras.
Peeper DS; Dannenberg JH; Douma S; te Riele H; Bernards R
Nat Cell Biol; 2001 Feb; 3(2):198-203. PubMed ID: 11175753
[TBL] [Abstract][Full Text] [Related]
15. E2F1 uses the ATM signaling pathway to induce p53 and Chk2 phosphorylation and apoptosis.
Powers JT; Hong S; Mayhew CN; Rogers PM; Knudsen ES; Johnson DG
Mol Cancer Res; 2004 Apr; 2(4):203-14. PubMed ID: 15140942
[TBL] [Abstract][Full Text] [Related]
16. p53 in breast cancer subtypes and new insights into response to chemotherapy.
Bertheau P; Lehmann-Che J; Varna M; Dumay A; Poirot B; Porcher R; Turpin E; Plassa LF; de Roquancourt A; Bourstyn E; de Cremoux P; Janin A; Giacchetti S; Espié M; de Thé H
Breast; 2013 Aug; 22 Suppl 2():S27-9. PubMed ID: 24074787
[TBL] [Abstract][Full Text] [Related]
17. Expression of hepaCAM is downregulated in cancers and induces senescence-like growth arrest via a p53/p21-dependent pathway in human breast cancer cells.
Moh MC; Zhang T; Lee LH; Shen S
Carcinogenesis; 2008 Dec; 29(12):2298-305. PubMed ID: 18845560
[TBL] [Abstract][Full Text] [Related]
18. Activation of a cAMP pathway and induction of melanogenesis correlate with association of p16(INK4) and p27(KIP1) to CDKs, loss of E2F-binding activity, and premature senescence of human melanocytes.
Haddad MM; Xu W; Schwahn DJ; Liao F; Medrano EE
Exp Cell Res; 1999 Dec; 253(2):561-72. PubMed ID: 10585280
[TBL] [Abstract][Full Text] [Related]
19. p53 Suppresses E2F1-dependent PLK1 expression upon DNA damage by forming p53-E2F1-DNA complex.
Zhou Z; Cao JX; Li SY; An GS; Ni JH; Jia HT
Exp Cell Res; 2013 Dec; 319(20):3104-15. PubMed ID: 24076372
[TBL] [Abstract][Full Text] [Related]
20. Involvement of E2F1 transcriptional activity in cadmium-induced cell-cycle arrest at G1 in human lung fibroblasts.
Choi YJ; Yin HQ; Suh HR; Lee YJ; Park SR; Lee BH
Environ Mol Mutagen; 2011 Mar; 52(2):145-52. PubMed ID: 20839231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
